TRACK(S): GEN, OTO
Moderator: Russell B. Smith, MD, FACS, Jacksonville, FL
Co-Moderator: Linwah Yip, MD, FACS, Pittsburgh, PA
The incidence of thyroid cancer and thyroid surgery is increasing each year. Many lesions are removed based on indeterminate fine-needle biopsy results by the Bethesda classification system. In indeterminate needle biopsy results, a challenge remains for guiding patients with the safest options for care. Recently, genetic evaluation of thyroid needle biopsy samples has become available to help with decision making for indeterminate lesions. In this session, experts will provide their own approach to when they consider genetic testing of value in the evaluation of thyroid nodules. Emphasis will be placed on studies that demonstrate sensitivity and specificity of genetic testing and how cost may relate to outcomes.
Presentations and Speakers
Russell B. Smith, MD, FACS, Jacksonville, FL
Afirma and Rosetta Testing for Indeterminate Nodules
Jennifer L. Marti, MD, FACS, New York, NY
ThyroSeq and ThyGenX/ThyraMIR Testing for Indeterminate Nodules
Michael W. Yeh, MD, FACS, Los Angeles, CA
Molecular Testing in Unique Populations
Erik K. Alexander, MD, Boston, MA
Molecular Testing: Does It Really Help?
Jon Russell, MD
Linwah Yip, MD, FACS, Pittsburgh, PA